SGLT2 inhibitors for treating heart failure and chronic kidney disease

Published on 31 Aug 2022
Last Updated on 02 Jan 2024

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Empagliflozin 10 mg and 25 mg tablets

in line with its registered indications for treating heart failure and chronic kidney disease, in view of favourable clinical and cost-effectiveness.

Subsidy status

Empagliflozin 10 mg and 25 mg tablets are recommended for inclusion on the Standard Drug List (SDL) from 1 November 2023.

Of note, dapagliflozin 5 mg and 10 mg tablets will be delisted from the MOH List of Subsidised Drugs with effect from 1 August 2024 due to unfavourable cost-effectiveness compared with empagliflozin.

SGLT2 inhibitors for treating heart failure and chronic kidney disease (Updated 2 Jan 2024) [PDF, 1 MB]

PES SGLT2 inhibitors for treating heart failure and chronic kidney disease (Updated 2 Jan 2024) [PDF, 82 KB]